Cargando…
Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review
BACKGROUND: Our goal is to review current literature regarding the role of multi-parametric magnetic resonance imaging (mpMRI) in the active surveillance (AS) of prostate cancer (PCa) and identify trends in rate of reclassification of risk category, performance of fusion biopsy (FB) versus systemati...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297445/ https://www.ncbi.nlm.nih.gov/pubmed/35872881 http://dx.doi.org/10.1177/17562872221106883 |
_version_ | 1784750478998896640 |
---|---|
author | Ellis, Elizabeth E. Frye, Thomas P. |
author_facet | Ellis, Elizabeth E. Frye, Thomas P. |
author_sort | Ellis, Elizabeth E. |
collection | PubMed |
description | BACKGROUND: Our goal is to review current literature regarding the role of multi-parametric magnetic resonance imaging (mpMRI) in the active surveillance (AS) of prostate cancer (PCa) and identify trends in rate of reclassification of risk category, performance of fusion biopsy (FB) versus systematic biopsy (SB), and progression-free survival. METHODS: We performed a comprehensive literature search in PubMed and identified 121 articles. A narrative summary was performed. RESULTS: Thirty-two articles were chosen to be featured in this review. SB and FB are complementary in detecting higher-grade disease in follow-up. While FB was more likely than SB to detect clinically significant disease, FB missed 6.4–11% of clinically significant disease. Imaging factors that predicted upgrading include number of lesions on magnetic resonance imaging (MRI), lesion density, and MRI suspicion level. CONCLUSION: Incorporating mpMRI FB in conjunction with SB should be part of contemporary AS protocols. mpMRI should additionally be used routinely for follow-up; however, mpMRI is not currently sensitive enough in detecting disease progression to replace biopsy in the surveillance protocol. |
format | Online Article Text |
id | pubmed-9297445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-92974452022-07-21 Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review Ellis, Elizabeth E. Frye, Thomas P. Ther Adv Urol Current Best Practice for Prostate Biopsy: What is the evidence? BACKGROUND: Our goal is to review current literature regarding the role of multi-parametric magnetic resonance imaging (mpMRI) in the active surveillance (AS) of prostate cancer (PCa) and identify trends in rate of reclassification of risk category, performance of fusion biopsy (FB) versus systematic biopsy (SB), and progression-free survival. METHODS: We performed a comprehensive literature search in PubMed and identified 121 articles. A narrative summary was performed. RESULTS: Thirty-two articles were chosen to be featured in this review. SB and FB are complementary in detecting higher-grade disease in follow-up. While FB was more likely than SB to detect clinically significant disease, FB missed 6.4–11% of clinically significant disease. Imaging factors that predicted upgrading include number of lesions on magnetic resonance imaging (MRI), lesion density, and MRI suspicion level. CONCLUSION: Incorporating mpMRI FB in conjunction with SB should be part of contemporary AS protocols. mpMRI should additionally be used routinely for follow-up; however, mpMRI is not currently sensitive enough in detecting disease progression to replace biopsy in the surveillance protocol. SAGE Publications 2022-07-18 /pmc/articles/PMC9297445/ /pubmed/35872881 http://dx.doi.org/10.1177/17562872221106883 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Current Best Practice for Prostate Biopsy: What is the evidence? Ellis, Elizabeth E. Frye, Thomas P. Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review |
title | Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review |
title_full | Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review |
title_fullStr | Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review |
title_full_unstemmed | Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review |
title_short | Role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review |
title_sort | role of multi-parametric magnetic resonance imaging fusion biopsy in active surveillance of prostate cancer: a systematic review |
topic | Current Best Practice for Prostate Biopsy: What is the evidence? |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297445/ https://www.ncbi.nlm.nih.gov/pubmed/35872881 http://dx.doi.org/10.1177/17562872221106883 |
work_keys_str_mv | AT elliselizabethe roleofmultiparametricmagneticresonanceimagingfusionbiopsyinactivesurveillanceofprostatecancerasystematicreview AT fryethomasp roleofmultiparametricmagneticresonanceimagingfusionbiopsyinactivesurveillanceofprostatecancerasystematicreview |